Bert van der Reijden

448 total citations
13 papers, 314 citations indexed

About

Bert van der Reijden is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Bert van der Reijden has authored 13 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 6 papers in Molecular Biology and 2 papers in Oncology. Recurrent topics in Bert van der Reijden's work include Acute Myeloid Leukemia Research (5 papers), RNA modifications and cancer (2 papers) and Hematopoietic Stem Cell Transplantation (2 papers). Bert van der Reijden is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), RNA modifications and cancer (2 papers) and Hematopoietic Stem Cell Transplantation (2 papers). Bert van der Reijden collaborates with scholars based in Netherlands, Germany and United States. Bert van der Reijden's co-authors include Joop H. Jansen, Hubert Serve, Dawn E. Quelle, Ming Hu, Carsten Müller‐Tidow, Scott W. Hiebert, Pier Paolo Pandolfi, John Nip, John L. Cleveland and Bryan Linggi and has published in prestigious journals such as Nature Medicine, Blood and Genes Chromosomes and Cancer.

In The Last Decade

Bert van der Reijden

13 papers receiving 311 citations

Peers

Countries citing papers authored by Bert van der Reijden

Since Specialization

Citations

This map shows the geographic impact of Bert van der Reijden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bert van der Reijden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bert van der Reijden more than expected).

Fields of papers citing papers by Bert van der Reijden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bert van der Reijden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bert van der Reijden. The network helps show where Bert van der Reijden may publish in the future.

Co-authorship network of co-authors of Bert van der Reijden

This figure shows the co-authorship network connecting the top 25 collaborators of Bert van der Reijden. A scholar is included among the top collaborators of Bert van der Reijden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bert van der Reijden. Bert van der Reijden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Purging human ovarian cortex of contaminating leukaemic cells by targeting the mitotic catastrophe signalling pathway 2021 ·Journal of Assisted Reproduction and Genetics ·(unknown), C.L. Mulder, Bert van der Reijden, Norah M. van Mello, (unknown), (unknown), D.D.M. Braat, C. C. M. Beerendonk, Ronald Peek	14
2	CBFβ-MYH11 interferes with megakaryocyte differentiation via modulating a gene program that includes GATA2 and KLF1 2019 ·Blood Cancer Journal ·Guoqiang Yi, Amit Mandoli, (unknown), Esther Tijchon, (unknown), (unknown), Marten Hansen, Bowon Kim, Luan N. Nguyen, Pascal W.T.C. Jansen, Michiel Vermeulen, Bert van der Reijden, Emile van den Akker, Jonathan Bond, Joost H.A. Martens	7
3	S847 DISTINCT AND COMMON DEREGULATED PATHWAYS IN RUNX1, GATA1 AND GFI1B ASSOCIATED BLEEDING DISORDERS 2019 ·HemaSphere ·(unknown), Anna E. Marneth, Floris van Alphen, Jeroen W. A. Jansen, (unknown), Saskia E.M. Schols, Sonja de Munnik, A. Simons, Emile van den Akker, Alexander B. Meijer, Bert van der Reijden	1
4	Generation and characterization of a human iPSC line SANi005-A containing the gray platelet associated heterozygous mutation p.Q287* in GFI1B 2017 ·Stem Cell Research ·Marten Hansen, Eszter Varga, (unknown), Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, (unknown), Marieke von Lindern, Bert van der Reijden, Emile van den Akker	2
5	Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial 2017 ·Genes Chromosomes and Cancer ·Marian Stevens‐Kroef, Daniël Olde Weghuis, (unknown), Bert van der Reijden, Eline M.P. Cremers, Canan Alhan, Theresia M. Westers, Heleen Visser-Wisselaar, Dana Chiţu, Sónia M. P. R. M. Cunha, Edo Vellenga, Saskia K. Klein, Pierre W. Wijermans, Georgine E. de Greef, M Schaafsma, Petra Muus, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Joop H. Jansen	13
6	Generation and characterization of human iPSC line MML-6838-Cl2 from mobilized peripheral blood derived megakaryoblasts 2016 ·Stem Cell Research ·Marten Hansen, Eszter Varga, (unknown), Nelleke P.M. Brouwer, (unknown), Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Tarik Möröy, Bert van der Reijden, Marieke von Lindern, Emile van den Akker	11
7	Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation 2012 ·Biology of Blood and Marrow Transplantation ·Willemijn Hobo, Kelly Broen, Walter J. F. M. van der Velden, (unknown), (unknown), (unknown), Michel G.D. Kester, Hanny Fredrix, Joop H. Jansen, Bert van der Reijden, J.H. Frederik Falkenburg, Théo de Witte, Frank Preijers, (unknown), Ton Feuth, Nicole M. A. Blijlevens, Nicolaas Schaap, Harry Dolstra	37
8	A Human Variant of Growth Factor Independence 1 (GFI136N) Predisposes to Myeloid Leukemia In Mice 2010 ·Blood ·Cyrus Khandanpour, Lothar Vaßen, Marie‐Claude Gaudreau, (unknown), Bert van der Reijden, Joop H. Jansen, (unknown), Tarik Möröy	1
9	P052 Acquired mutations in TET2 are common in myelodysplastic syndromes 2009 ·Leukemia Research ·Saskia Langemeijer, Roland P. Kuiper, M Berends, Ruth Knops, Mariam G. Aslanyan, Marion Massop, Patricia van den Hoogen, Ad Geurts van Kessel, (unknown), Estelle Verburgh, A Hagemeijer, Peter Vandenberghe, T. de Witte, Bert van der Reijden, (unknown)	2
10	Chemokine Induction by All-Trans Retinoic Acid in Acute Promyelocytic Leukemia - Triggering the Retinoic Acid Syndrome 2008 ·Blood ·(unknown), Jeroen L. A. Pennings, (unknown), P. Linssen, Petra Muus, (unknown), Richard Huijbens, Théo de Witte, Bert van der Reijden, Joop H. Jansen	1
11	Sequence Polymorphism Systems for Quantitative Real-Time Polymerase Chain Reaction to Characterize Hematopoietic Chimerism—High Informativity and Sensitivity As Well As Excellent Reproducibility and Precision of Measurement 2007 ·PubMed ·André Willasch, (unknown), (unknown), Nona Shayegi, Hermann Kreyenberg, Selim Kuçi, Gerrit Weber, Bert van der Reijden, D. Niethammer, Thomas Klingebiel, Peter Bader	22
12	The t(8;21) fusion protein, AML1–ETO, specifically represses the transcription of the p14ARF tumor suppressor in acute myeloid leukemia 2002 ·Nature Medicine ·Bryan Linggi, Carsten Müller‐Tidow, Louis van de Locht, Ming Hu, John Nip, Hubert Serve, Wolfgang E. Berdel, Bert van der Reijden, Dawn E. Quelle, Janet D. Rowley, John L. Cleveland, Joop H. Jansen, Pier Paolo Pandolfi, Scott W. Hiebert	202
13	Analysis of clonality by HUMARA PCR in high risk MDS patients before and after intensive anti-leukemic treatment 2001 ·Blood ·Johannes van Dijk, Manuel Aivado, Michel Delforge, Robert J. van Soest, Gianfranco Catalano, B. Johansson, Isabelle Tigaud, M Jotterand-Bellomo, Jaroslav Čermák, (unknown), Stefan Suciu, Bert van der Reijden, Joop H. Jansen, Petra Muus, T. de Witte	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact